KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Notes Payables (2018 - 2025)

Historic Notes Payables for Biogen (BIIB) over the last 13 years, with Q3 2025 value amounting to $6.3 billion.

  • Biogen's Notes Payables fell 13.98% to $6.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 billion, marking a year-over-year decrease of 13.98%. This contributed to the annual value of $6.3 billion for FY2024, which is 925.89% down from last year.
  • Latest data reveals that Biogen reported Notes Payables of $6.3 billion as of Q3 2025, which was down 13.98% from $6.3 billion recorded in Q2 2025.
  • Biogen's 5-year Notes Payables high stood at $7.3 billion for Q2 2022, and its period low was $6.3 billion during Q3 2022.
  • Moreover, its 5-year median value for Notes Payables was $6.3 billion (2024), whereas its average is $6.6 billion.
  • As far as peak fluctuations go, Biogen's Notes Payables plummeted by 1364.17% in 2022, and later skyrocketed by 1046.33% in 2023.
  • Quarter analysis of 5 years shows Biogen's Notes Payables stood at $7.3 billion in 2021, then decreased by 13.64% to $6.3 billion in 2022, then rose by 10.46% to $6.9 billion in 2023, then fell by 9.26% to $6.3 billion in 2024, then dropped by 0.17% to $6.3 billion in 2025.
  • Its last three reported values are $6.3 billion in Q3 2025, $6.3 billion for Q2 2025, and $6.3 billion during Q1 2025.